Evolution of systemic therapy for advanced pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Evolution of systemic therapy for advanced pancreatic cancer.

Evolution of systemic therapy for advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33557413

about

Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation Potential effects of Mina53 on tumor growth in human pancreatic cancer Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer Oncocytic-type intraductal papillary mucinous neoplasm (IPMN)-derived invasive oncocytic pancreatic carcinoma with brain metastasis - a case report.Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile Vitamin d and pancreatic cancer-an update.Current state of surgical management of pancreatic cancer.Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by noninvasive radiofrequency field treatment.FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer.Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.What's new in treatment of pancreatic cancer: a patent review (2010-2017).High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study.Pancreatic cancer and supportive care--pancreatic exocrine insufficiency negatively impacts on quality of life.Treatment of pancreatic cancer with intravenous vitamin C: a case report.Inhibition of pancreatic cancer stem cells by Rauwolfia vomitoria extract A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer

P2860

Q26740619-66E335C1-FEEE-4153-A3A1-4B7FD8063455 Q28552789-3710246B-98BE-4E92-8E7F-6F5BA699BF5B Q33755366-3B17A2CE-1E40-4693-AF84-D8E476F15372 Q33857806-FA454B66-E6A8-4DEF-97ED-A37669C3924F Q35613655-480BB1D7-F8E2-4268-B3DA-1F857EF7A538 Q36351453-09E43413-1751-4584-B2A5-AAEE0633A67B Q36369793-17B93DDC-8832-40AB-BFCF-6D108ECFFBA2 Q36524171-747E648A-8F11-43A7-9ACF-5C824A5209FB Q36817494-63BDAC8C-2D8E-4A8B-8BCE-3A0F535FF332 Q37129757-FC09D4E3-6258-411B-9D93-61DFA0A96CFE Q37129872-019498B1-202E-42F0-9534-E11CFC97DF9B Q37564404-ECFF4026-3C08-4D39-9CC2-3EF6216E382F Q38910968-C9EE40D5-A3DF-4180-99C1-A59B61813AFE Q39001305-EB5ED02B-3783-4A45-B12A-6C6656328AB4 Q39014390-2CE0B6AC-768B-4048-A2B9-AA86470E5CDC Q39406815-9D07A5AE-4BFE-4382-8235-8433E903B4B6 Q47112954-05ECFBCB-A686-4907-9C34-20745C4400B7 Q48301649-8AAF4073-CDB3-48A8-AC1C-83303F841AEF Q50042500-FC72583E-C020-4CA6-A6A3-EA7957170DC8 Q57074008-53DA968F-A545-42F5-82BF-BCE196C78B98 Q58819336-43244BF9-3C22-49CF-88EF-F5D418950A6A

P2860

Evolution of systemic therapy for advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33557413

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Evolution of systemic therapy for advanced pancreatic cancer.

@ast

Evolution of systemic therapy for advanced pancreatic cancer.

@en

Evolution of systemic therapy for advanced pancreatic cancer.

@nl

type

label

Evolution of systemic therapy for advanced pancreatic cancer.

@ast

Evolution of systemic therapy for advanced pancreatic cancer.

@en

Evolution of systemic therapy for advanced pancreatic cancer.

@nl

prefLabel

Evolution of systemic therapy for advanced pancreatic cancer.

@ast

Evolution of systemic therapy for advanced pancreatic cancer.

@en

Evolution of systemic therapy for advanced pancreatic cancer.

@nl

P1433

Q33557413-9E427377-EC6E-40EB-A25B-BDFD65F54820

P1476

Q33557413-962E93D2-2BF3-4A3C-883D-FA284F45592C

P2093

Q33557413-6FB497CA-E0AA-4B62-AAE9-29CC519E3446

Q33557413-A38C074A-46B7-42F2-8D74-BFEDCB1892F4

P2860

Q33557413-05897657-6A88-49CC-BF3B-15D5B58EC6AD

Q33557413-0677F866-65C4-4E8F-90EB-97854EAA900D

Q33557413-0852DA16-3063-4218-A076-323708EBDD22

Q33557413-0CB9FA86-372C-46AF-B10B-24743518C06E

Q33557413-100D630A-6988-459A-871B-19CE73F9BDC9

Q33557413-1343CF90-6D4E-48CF-9BE0-3737C279CE3A

Q33557413-15E2C951-7E35-4A7F-8704-D80967C8EC0C

Q33557413-1A8D4250-9917-4649-B42B-B817D7803EF9

Q33557413-206FBFB7-2FF7-4C7C-A873-AD316EE7798E

Q33557413-223C4476-FFA7-4E99-AB35-D16A9B168C73

P304

Q33557413-C31D09CD-AC3C-4350-932F-3C961D052997

P31

Q33557413-9552AAD7-6794-4EB2-8C7D-A807342734BF

P356

Q33557413-A9019E71-6591-46BD-AFC8-DC66AB30AA1A

P433

Q33557413-2FF5A5DF-5A4A-44E3-9849-D031AE02D3AC

P478

Q33557413-B4BFD26F-C9CA-4A2F-B542-65D698AB2140

P577

Q33557413-7100C527-01B1-454C-8E8C-93FB89DFBDC1

P698

Q33557413-2426A560-05AF-4294-8B2D-FA7FBD366629

P356

P1433

Expert Review of Anticancer Therapy

P1476

Evolution of systemic therapy for advanced pancreatic cancer.

@en

P2093

Daniel Renouf

http://www.w3.org/2001/XMLSchema#string

Malcolm Moore

http://www.w3.org/2001/XMLSchema#string

P2860

Pathways for aberrant angiogenesis in pancreatic cancer

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Cancer statistics, 2008

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

P304

529-540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.10.21

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20397918

http://www.w3.org/2001/XMLSchema#string